AcelRx Pharmaceuticals Inc. is having a hard time explaining FDA’s request for a new clinical trial of its patient-activated acute pain drug/device system Zalviso.
Zalviso contains a novel, sublingual formulation of the opioid sufentanil for use in the hospital setting after surgery. With a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?